Literature DB >> 1083786

In vitro stimulation of murine lymphoid cell cultures by levamisole.

V J Merluzzi, A M Badger, C W Kaiser, S R Cooperband.   

Abstract

Levamisole has been reported to act as an immunological adjuvant. Experiments reported here on the effect of this agent on a variety of murine lymphoid culture systems were designed to gain an insight into its mechanism of action. We have found levamisole to be a weak mitogen for mouse spleen cells producing a dose related response which peaks at 48 hr in culture. The drug acted to augment the response of spleen cells to sub-optimal concentrations of concanavalin A, but had no unusual effect on the lipopolysaccharide stimulation of B-cell DNA synthesis in vitro. Levamisole was directly stimulatory on enriched T-cell populations and was found to have two actions: (1) to stimulate a subpopulation of T cells and (2) to augment the response of suboptimal mitogen concentrations of concanavalin A. In addition, we have found that murine thymocytes stimulated by concanavalin A were greatly potentiated in the presence of levamisole, but this population of cells could not be stimulated directly by the drug.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1083786      PMCID: PMC1538428     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  13 in total

1.  [Action of phenylimidothiazole (tetramisole) on the graft versus host reaction. Role of macrophages].

Authors:  G Renoux; M Renoux
Journal:  C R Acad Hebd Seances Acad Sci D       Date:  1972-06-12

2.  Letter: Treatment of aphthous stomatitis.

Authors:  H Verhaegen; J De Cree; J Brugmans
Journal:  Lancet       Date:  1973-10-13       Impact factor: 79.321

3.  In vitro stimulation of spleen cell cultures by poly I: poly C and levamisole.

Authors:  W A Woods; M J Siegel; M A Chirigos
Journal:  Cell Immunol       Date:  1974-11       Impact factor: 4.868

4.  Levamisole inactive in treatment of four animal tumours.

Authors:  C W Potter; I Carr; R Jennings; R C Rees; F McGinty; V M Richardson
Journal:  Nature       Date:  1974-06-07       Impact factor: 49.962

5.  Drug-induced restoration of cutaneous delayed hypersensitivity in anergic patients with cancer.

Authors:  D Tripodi; L C Parks; J Brugmans
Journal:  N Engl J Med       Date:  1973-08-16       Impact factor: 91.245

6.  Influence of tetramisole and its optical isomers on the mononuclear phagocytic system. Effect on carbon clearance in mice.

Authors:  J Hoebeke; G Franchi
Journal:  J Reticuloendothel Soc       Date:  1973-09

7.  Augmentation of chemotherapeutically induced remission of a murine leukemia by a chemical immunoadjuvant.

Authors:  M A Chirigos; J W Pearson; J Pryor
Journal:  Cancer Res       Date:  1973-11       Impact factor: 12.701

8.  [Immunostimulating action of phenylimidothiazole derivatives on spleen antibody-producing cells].

Authors:  G Renoux; M Renoux
Journal:  C R Acad Hebd Seances Acad Sci D       Date:  1972-01-31

9.  [Restoration by phenylimidothiazole of the immunological response of aged mice].

Authors:  G Renoux; M Renoux
Journal:  C R Acad Hebd Seances Acad Sci D       Date:  1972-05-29

10.  Tetramisole (R 8299), a new, potent broad spectrum anthelmintic.

Authors:  D Thienpont; O F Vanparijs; A H Raeymaekers; J Vandenberk; J A Demoen; F T Allewijn; R P Marsboom; C J Niemegeers; K H Schellekens; P A Janssen
Journal:  Nature       Date:  1966-03-12       Impact factor: 49.962

View more
  4 in total

1.  Immunological aspects of candidal vaginitis.

Authors:  J R Hobbs; D Brigden; F Davidson; M Kahan; J K Oates
Journal:  Proc R Soc Med       Date:  1977

2.  The experimental and clinical use of immune-modulating drugs in the prophylaxis and treatment of infections.

Authors:  J Drews
Journal:  Infection       Date:  1985       Impact factor: 3.553

3.  Immunostimulation. Clinical and experimental perspectives.

Authors:  J Drews
Journal:  Klin Wochenschr       Date:  1984-03-15

4.  The experimental and clinical use of immune-modulating drugs in the prophylaxis and treatment of infections.

Authors:  J Drews
Journal:  Infection       Date:  1984 Mar-Apr       Impact factor: 3.553

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.